Wellness & Lifestyle

NyquistAI is an AI-powered platform uniquely tailored for Life Sciences innovators, designed to reshape global intelligence and enhance workflows. It offers several specialized products, including Nyquist Pharma for clinical pipeline and on-market therapy data, Nyquist MedTech for global clinical and regulatory medical device data, and Nyquist IQ for automating data analysis, synthesis, and summarization. Nyquist Scholar revolutionizes systematic literature reviews by streamlining completion times and optimizing search results. The platform is fine-tuned with over 1 billion Life Sciences data points, enabling it to understand context, uncover unsearchable insights, and provide relevant global results. It also offers custom solutions and integrates with tools like ChatGPT and Claude via MCP Server.

Health OneClick specializes in transforming healthcare data into valuable knowledge for the health and pharmaceutical sectors. The platform leverages advanced predictive models based on Artificial Intelligence, Machine Learning, Natural Language Processing (NLP), and Data Mining to anticipate needs and enhance Real World Evidence (RWE). It supports companies in managing their data lifecycle, ensuring interoperability, and anonymizing sensitive patient information in compliance with GDPR. By integrating data from various sources, Health OneClick helps identify patterns and trends in clinical practice, leading to more precise diagnoses, early disease detection, and improved patient care. The ultimate goal is to empower organizations to become "Data Driven," basing decisions on advanced analytical insights.

Modella AI is a leader in developing artificial intelligence solutions specifically for biomedical imaging, with a strong emphasis on pathology. The company creates innovative AI models that integrate multimodal biomarker data to significantly enhance diagnostic, prognostic, and and therapeutic workflows in healthcare. Key offerings include PathChat, an AI copilot for pathology case consultation, capable of summarizing and creating pathology reports from various sources, and Judith, an AI agent designed to automate AI model development for biomedical image analysis and scientific discovery. Modella AI aims to revolutionize patient care through generative AI for medical imaging and has been acquired by AstraZeneca to advance AI-driven oncology R&D.

P360 offers a unified platform specifically designed for the pharmaceutical industry, integrating AI automation and data-driven insights to streamline operations and enhance HCP engagement. The platform is divided into three core modules: Connect, Activate, and Automate. Connect facilitates app-free HCP engagement through compliant SMS, WhatsApp, voice, and video calls, ensuring all interactions are CRM-logged and audit-ready. Activate transforms scattered pharma data into actionable, AI-powered insights, improving analytics, sales, and marketing operations. Automate provides in-app AI agents for CRM and internal research, enabling compliant content drafting, summarization, and automated next steps. P360 is trusted by top pharma companies globally for its enterprise-grade compliance and scalability.

Mindstate Design Labs is a clinical-stage AI neuroengineering platform and drug development company focused on creating novel mental health therapeutics. Their proprietary Osmanthus platform leverages AI, including multi-agent large language models and Bayesian neural networks, to synthesize 60,000 human reports of psychoactive drug effects with biochemical data. This allows them to identify how specific neurotransmitter receptor combinations produce distinct emotional and cognitive states. The company is developing compounds like MSD-001, designed to induce states such as empathy or awe, offering new therapeutic possibilities for psychological afflictions. Their pipeline includes programs targeting precision-designed emotional and cognitive states and novel central nervous system targets.

Converge Bio is a generative AI lab specifically designed for the life sciences, aiming to accelerate drug development. The platform leverages GenAI for innovations in discovery, molecule design, and manufacturing, creating therapies for tomorrow, today. Key offerings include Antibody Design & Screening (ConvergeAB™) for engineering precise antibodies, Gene Expression Optimization (ConvergeGEO™) to maximize protein yields, and Target & Biomarker Discovery (ConvergeCELL™) for identifying novel targets and optimizing clinical trials. The computational lab utilizes a bio-LLM library with foundation models across biological languages, enhanced with curated data and fine-tuned for specific tasks. It emphasizes data privacy, full customer control over generated assets, and a fully managed infrastructure.

IntraIntel.AI is a production-ready enterprise AI platform designed to transform internal data into actionable intelligence without compromising security. It enables organizations to deploy specialized AI agents for automating technical documentation, regulatory compliance, clinical workflows, and operational processes across all data sources, requiring no data migration. The platform operates entirely within a client's infrastructure, ensuring data sovereignty and compliance with standards like HIPAA, GDPR, and SOC 2. It supports seamless integration with major cloud platforms such as Google Drive, Dropbox, OneDrive, AWS S3, and Azure Blob Storage. IntraIntel.AI offers custom AI model training, multi-agent orchestration, RAG architecture, and a leadership dashboard, delivering secure and private AI search capabilities.

VedTechBio Research Pvt Ltd is a biopharmaceutical solutions company specializing in drug discovery, development, and marketing. The company aims to bridge the gap between technological advancements and practical applications in healthcare, translating scientific discoveries into tangible solutions that positively impact patient lives. VedTechBio offers end-to-end solutions across the entire drug discovery and development value chain, utilizing state-of-the-art technology including drug technologies, precision medicine, artificial intelligence, machine learning, and real-world medicine. Their proprietary tools, such as RxAgentAI, accelerate these processes by embracing the transformative potential of Generative AI and Machine Learning, crafting custom solutions for pharma innovation.

Trueblue specializes in providing AI-powered solutions for the pharmaceutical and life science industries. Their offerings include AiDEA Suite, which leverages AI to accelerate daily tasks for commercial teams, manage events, and improve retail performance. MyAiDEA specifically enhances CRM systems with AI for smart, multichannel HCP engagement, offering features like streamlined operations, custom interactions, data insights, and an AI voice assistant. Additionally, NOVA is a business intelligence platform designed to harmonize and democratize data, enabling teams to uncover valuable insights, improve efficiency, and drive sales and marketing results. Trueblue's solutions are built on Microsoft technologies like Dynamics 365, Power BI, and Azure, ensuring a robust and scalable infrastructure.

Optimum Data Analytics (ODA) is a leading provider of AI and analytics solutions, dedicated to transforming raw data into intelligence. They empower enterprises with custom-built AI, Data Science, and Business Intelligence solutions, delivering measurable ROI across sectors like life sciences, healthcare, supply chain, agriculture, and finance. ODA offers a range of services including Generative AI, Agentic AI, AI/ML Solutions, Data Engineering, and Computer Vision. Their expertise extends to developing domain-specific bots, implementing RAG-based text extraction, and providing advanced machine learning algorithms for predictive analytics. ODA prides itself on understanding client problems, proposing tailored solutions, and ensuring a smooth and impactful success journey for their partners.

emtelligent delivers medical-grade AI solutions designed to transform unstructured clinical data into actionable insights. Its cutting-edge Natural Language Processing (NLP) and Large Language Model (LLM) technology provide high accuracy for clinical data extraction and medical chart review. The platform supports various healthcare use cases, including prior authorization, insurance review, risk adjustment, clinical trial screening, and chronic care management. Key features include an intuitive review interface, intelligent search, patient summarization, and complete chart view. emtelligent also offers robust document processing capabilities like automatic classification, intelligent document splitting, and clinical OCR to prepare complex medical documents for AI workflows, ensuring enhanced auditability and seamless integration with existing healthcare systems.

Prudentia Sciences offers an AI-powered platform designed to build conviction in the science behind every deal in the biopharma sector. It helps evaluate assets faster for licensing, acquisition, and investment by replacing fragmented workflows with a single, integrated system. The platform connects internal and external data, ingests information from VDRs and other datasets, and integrates with CRMs. It applies structured evaluation frameworks tailored to an asset’s biology, modality, and stage, ensuring rigorous scientific assessment and continuous re-evaluation as new data emerges. Prudentia Sciences also contextualizes deals within the competitive landscape, identifies differentiation and risks, and supports valuation modeling for M&A and partnerships. The AI reasoning is grounded in evidence, trained for therapeutic areas and modalities, and ensures end-to-end data provenance with human-in-the-loop validation.

MOLCURE Inc. is an AI company dedicated to accelerating drug discovery by integrating machine learning, biotechnology, and robotics. Their core technology is an evolving AI platform featuring specialized algorithms for biological data and a rapid in-house learning loop. Key strengths include a proprietary Antibody Large Language Model (LLM) built from scratch, a database with over 1 billion proprietary datapoints, and an in-house wet lab for directed evolution experiments and next-generation sequencing. MOLCURE offers various collaboration models, including end-to-end support for AI-driven molecular design, AI-powered de novo discovery of novel molecules, and AI-driven lead optimization for existing candidate molecules. They also provide consulting services to leverage AI technologies in drug discovery processes.

Isomorphic Labs is at the forefront of drug discovery, leveraging advanced AI to transform how new medicines are developed. Building on the Nobel-winning AlphaFold system, the company employs an interdisciplinary team of drug discovery experts and machine learning specialists. They have developed powerful predictive and generative AI models designed to accelerate scientific discovery at digital speed. Their mission is to advance human health by enabling faster breakthroughs and creating life-changing medicines, ultimately aiming to solve all disease with the help of AI. The Isomorphic Labs Drug Design Engine represents a significant leap beyond AlphaFold, showcasing their commitment to innovation in digital biology.

Deargen is an AI-first pharmatech company dedicated to transforming the future of treating undruggable diseases through the integration of AI and collective intelligence. Their Dr. UG AI platform leverages deep learning technology for genome data analysis, biomarker prediction, molecule selection, and optimization. Deargen discovers new disease targets and designs small molecules for novel drugs, enabling precision medicine. Their AI technology is applied across various new drug development strategies, including PROTAC, ADC, EPITOPE, AGONIST, and INHIBITOR pipelines.

Agrematch is an artificial intelligence company specializing in the discovery and development of sustainable bioactive compounds for the agriculture and food sectors. Its disruptive AI predictive system, AI4AI, leverages machine/deep learning algorithms and a proprietary database of billions of compounds to identify molecules with biological activity. The platform predicts and characterizes crucial compound attributes like toxicity, mode of action, compatibility, and environmental impact early in the screening process, accelerating development and mitigating downstream risks. Agrematch's unique approach allows for the rapid identification and validation of novel products, offering a significant advantage over traditional discovery methods.

Terray Therapeutics is at the forefront of small molecule drug discovery, utilizing a unique integrated full-stack AI platform. The company's approach emphasizes the synergy between wet lab science and advanced AI, generating high-quality data at an unprecedented scale. Their experimental dataset boasts over two billion unique target-ligand binding measurements, expanding by one billion quarterly. This precise, data-rich environment enables accurate molecular property prediction through deep learning regression models. Terray's closed-loop iteration process allows for a design-make-test-analyze cycle in less than a month per target, efficiently exploring chemical space and identifying potent, selective small molecules for various targets in parallel. This platform is designed to significantly improve the speed, cost, and success rate of drug discovery and development, with an internal pipeline focused on immunology and partnerships across diverse therapeutic areas.

LynxCare is a real-world data platform designed to unlock high-quality, OMOP-ready real-world evidence through its federated analytics and clinical Natural Language Processing (NLP) capabilities. The platform leverages a secure European hospital network to deliver validated Electronic Health Record (EHR) insights at scale, covering areas such as oncology, cardiology, and mental health. Key features include federated analytics, allowing patient data to remain within the hospital, and clinical NLP that enriches structured EHR data with outcomes, lines of therapy, and adverse events. LynxCare ensures data quality through five rigorous QA checks and supports multi-center, multi-country research collaborations while maintaining data privacy and regulatory compliance. It is active in Belgium, the Netherlands, France, and Germany, with expansion capabilities.

Latent Labs is a frontier AI lab dedicated to making biology programmable to transform health and sustainability. They build generative models that capture the fundamentals of biology, offering breakthrough AI solutions to gain unprecedented control over molecular biology. Their offerings include Latent-Y, an autonomous AI agent for drug design, Latent-X2, a frontier model for drug-like antibodies with low immunogenicity, and Latent-X, an atom-level frontier model for de novo protein binder design. These models empower partners to create new antibodies, optimize existing enzymes, and advance genetic engineering.

Creme Global advances global health, safety, and nutrition through world-class scientific modeling, data science, AI, and predictive capabilities. It serves consumers, manufacturers, and producers to create products that improve lives and contribute to sustainability. The platform offers AI-powered predictive modeling, advanced data collection, data analytics, and exposure and analysis tools for cosmetics, food safety, crop protection, and nutrition reformulation. Creme Global also provides expert services such as AI and predictive model development, data trusts, nutritional intake modeling, and AI-enhanced new product development. It works with leading food, cosmetic, and chemical companies, as well as major regulators in the US and Europe, to enable better data-based decisions and drive industry-wide insights.

Rivia is a unified data and AI analytics platform specifically designed for biotech clinical trials. It addresses the challenge of fragmented trial data by integrating various sources into a single, structured intelligence layer. The platform offers Rivia Core for data unification and harmonization, Rivia Detect for agentic data quality monitoring and issue resolution, and Rivia Spark for visual intelligence and AI-powered conversational patient profile analysis. Rivia aims to enhance decision-making, streamline operations, and improve safety monitoring for clinical teams, executives, and medical scientists, enabling faster and smarter decisions in clinical development.

Faro is an AI-powered platform specifically designed for accelerating clinical development within the biopharma industry. It provides an end-to-end solution for intelligent study design and execution, helping teams optimize protocols with data and real-time insights. The platform features document authoring capabilities to generate high-quality protocol drafts rapidly and workflow automation to expedite study startup, including automated EDC builds. Faro aims to deliver substantial potential savings in participant and site staff time, costs, and trial complexity, as evidenced by identified cost savings and avoided patient hours. It is trusted by industry leaders to enhance the efficiency and effectiveness of clinical trials.

Boltzmann Labs offers an AI-powered platform designed to revolutionize drug discovery. The platform accelerates critical stages of pharmaceutical development, including small molecule design, protein engineering, clinical trials, and multi-omics analysis. By leveraging artificial intelligence, Boltzmann Labs aims to provide data-driven precision medicine solutions, enhancing efficiency and accuracy in identifying targets, designing compounds, and analyzing complex biological data. This comprehensive approach supports researchers and pharmaceutical companies in bringing new therapies to market faster and more effectively.

arivis Cloud is a digital, cloud-based platform designed for biotech researchers to automate and customize image processing tasks. Equipped with an AI toolkit, it allows users to easily train deep learning models for complex feature segmentation in scientific images, all without needing to write any code. The platform offers customized image analysis workflows to improve throughput and reproducibility, making it ideal for automating mundane and repetitive tasks. Leveraging cloud infrastructure, arivis Cloud provides a scalable, secure, flexible, and mobile solution, helping to reduce costs associated with system hardware and software while ensuring reproducible results for large datasets.